180 Life Sciences Corporate Media Kit

21 a7nAChR Platform Led by Jonathan Rothbard and Larry Steinman Decade of research on immune suppression in multiple sclerosis led to realization of the importance of the a7 subunit of nicotinic Acetylcholine Receptor (nAChR) • a7 nAChR also a central factor in evolutionarily ancient neural circuit to control of inflammation (1,2) • Large pharma identified a7 as a pharmaceutical target for Alzheimer’s disease and schizophrenia ─ Multiple specific agonists developed ─ All shown to be safe, but did not meet milestones in human clinical trials ─ Strategic goal of 180 LIFE SCIENCES to repurpose drugs for inflammation (1) Rothbard JB, Rothbard JJ, Soares L, Fathman CG, and Steinman L. Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine. Proc Natl Acad Sci U S A. 2018 115:7081-7086. (2) Tracey KJ. Reflex control of immunity. Nat Rev Immunol. (2009) 9:418–28 Significant Unmet Need Existing Therapies Are Sub-Optimal Existing Therapy Issues Anti-inflammatory drugs (5-aminosalicylates, corticosteroids) × capability to induce remission is quite low × known deleterious side effects of steroids Immunosuppressants × long-term administration of thiopurine may correlate with an increased risk of developing lymphoma × cyclosporine leads to kidney damage Infliximab (anti-TNF) × serious adverse events, such as opportunistic infections, including tuberculosis, as well as congestive heart failure in cardiopathic patients • Nicotine binds a7 and is a known immune suppressive • A subgroup of patients who cease smoking subsequently acquire ulcerative colitis • Treatment of these patients with a7 agonist has a high probability of therapeutic success (can be viewed as nicotine replacement therapy without issues of addiction) 180 Life Sciences Corp. www.180lifesciences.com Q4 2020